Abstract:Background: An abscopal response describes radiotherapy-induced immune-mediated tumour regression at sites distant to the irradiated field. Granulocyte-macrophage colony-stimulating factor is a potent stimulator of dendritic cell maturation. We postulated that the exploitation of the pro-immunogenic effects of radiotherapy with granulocyte-macrophage colony-stimulating factor might result in abscopal responses among patients with metastatic cancer. Methods: Patients with stable or progressing metastatic solid tumours, on single-agent chemotherapy or hormonal therapy, with at least three distinct measurable sites of disease, were treated with concurrent radiotherapy (35 Gy in ten fractions, over 2 weeks) to one metastatic site and granulocyte-macrophage colony-stimulating factor (125 μg/m(2) subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy). This course was repeated, targeting a second metastatic site. A Simon's optimal two-stage design was chosen for this trial: an additional 19 patients could be enrolled in stage 2 only if at least one patient among the first ten had an abscopal response. If no abscopal responses were seen among the first ten patients, the study would be deemed futile and terminated. The primary endpoint was the proportion of patients with an abscopal response (defined as at least a 30% decrease in the longest diameter of the best responding abscopal lesion). Secondary endpoints were safety and survival. Analyses were done based on intention to treat. The trial has concluded accrual, and is registered with ClinicalTrials.gov, number NCT02474186. Findings: From April 7, 2003, to April 3, 2012, 41 patients with metastatic cancer were enrolled. In stage 1 of the Simon's two-stage design, ten patients were enrolled: four of the first ten patients had abscopal responses. Thus, the trial proceeded to stage 2, as planned, and an additional 19 patients were enrolled. Due to protocol amendments 12 further patients were enrolled. Abscopal responses occurred in eight (27·6%, 95% CI 12·7-47·2) of the first 29 patients, and 11 (26·8%, 95% CI 14·2-42·9) of 41 accrued patients (specifically in four patients with non-small-cell lung cancer, five with breast cancer, and two with thymic cancer). The most common grade 3-4 adverse events were fatigue (six patients) and haematological (ten patients). Additionally, a serious adverse event of grade 4 pulmonary embolism occurred in one patient. Interpretation: The combination of radiotherapy with granulocyte-macrophage colony-stimulating factor produced objective abscopal responses in some patients with metastatic solid tumours. This finding represents a promising approach to establish an in-situ anti-tumour vaccine. Further research is warranted in this area. Funding: New York University School of Medicine's Department of Radiation Oncology and Cancer Institute.

Abscopal Effect and Safety of Recurrent and Refractory Advanced Malignant Thymoma or Thymic Carcinoma Treated with Combined Therapy of Local Radiotherapy and Granulocyte-macrophage Colony-stimulating Factor

Abscopal Effects Induced by Radiotherapy Combined with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Recurrent or Refractory Metastatic Thymic Epithelial Tumors: A Single-Institution Experience

Combining SBRT with GM-CSF and Peg-IFNα to Induce Abscopal Effects in Previously Treated Patients with Stage IV Thymic Tumors

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial

Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review

[Abscopal effect: Myth or reality?]

Bystander Effect and Abscopal Effect in Recurrent Thymic Carcinoma Treated with Carbon-Ion Radiation Therapy: A Case Report

Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity

Abstract 364: Impact of Glucocorticoid in Patients with Locally Advanced Esophageal Cancer Treated with Concurrent Chemoradiotherapy

Systemic Effects of Radiation Therapy-Induced Abscopal Responses in Patients with Advanced Lung Cancer

Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer

Effect of Low-Dose Radiotherapy on Abscopal Responses to Hypofractionated Radiotherapy and Anti-Pd1 in Mice and NSCLC Patients.

Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer

Boosted abscopal effect from radiotherapy and pembrolizumab in anaplastic thyroid cancer: a mini-review and case report

A good response to anti-PD-1 monoclonal antibody plus SBRT in a patient with PD-L1-negative recurrent advanced esophageal cancer: a long-term follow-up case report of a possible abscopal effect

Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy

Effect of hypofractionated radiotherapy, PD-1 immunotherapy, and anti-angiogenic therapy on abscopal responses and the tumor microenvironment.

AB001. Surgical Resection Followed by Entire Hemithorax Irradiation in Patients with Stage IVa Thymoma: Preliminary Result of a Prospective Phase II Study

Abscopal effect of radiotherapy combined with immune checkpoint inhibitors

P1.17-001 the Optimal First-Line Treatment for Advanced Thymic Carcinomas

Combination of Thermal Ablation and Activated Functional Killer Cells Immunotherapy for Cancer: A Retrospective Study.